A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases.

ABSTRACT:

Background

Our research group has previously published a dosimetric planning study that demonstrated that a 60 Gy/10 fractions intralesional boost with whole-brain radiotherapy (WBRT) to 30 Gy/10 fractions was biologically equivalent with a stereotactic radiosurgery (SRS) boost of 18 Gy/1 fraction with 30 Gy/10 fractions WBRT. Helical tomotherapy (HT) was found to be dosimetrically equivalent to SRS in terms of target coverage and superior to SRS in terms of normal tissue tolerance. A phase I trial has been now completed at our institution with a total of 60 enrolled patients and 48 evaluable patients. The phase II dose has been determined to be the final phase I cohort dose of 60 Gy/10 fractions.

Methods/design

The objective of this clinical trial is to subject the final ph

SUBMITTER: Rodrigues G 

PROVIDER: S-EPMC3341183 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature